Synthetic Biologics Appoints VP Corporate Development
Executive Summary
Synthetic Biologics Inc. has appointed Dr Isaac J. Bright vice president of corporate development. Bright brings over 15 years of transactional and operational experience to the clinical stage company, which focuses on developing therapeutics to protect the gut microbiome. Prior to joining Synthetic Biologics, Bright was a partner at US private equity investment practice Merieux Development, before which he was vice president, corporate development and diagnostics at QuantaLife Inc.
You may also be interested in...
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Three New CMOs And CFOs Among This Week's Changes
Recent moves in the industry include C-suite shuffles at PureTech Health and Traws Pharma, plus Xencor gets a new chief financial officer.